Olympus (7733) investor relations material

Executive summary

• Revenue guidance was revised down due to ship holds in the SIS division and weaker U.S. GI performance, though Q3 saw 4% YoY growth led by Europe, emerging markets, and China, with FX tailwinds.

• U.S. GI underperformed in Q3 due to execution issues, not product competitiveness, but corrective actions and leadership changes are expected to drive Q4 growth.

• China returned to 5-6% growth in Q3 after prior declines, attributed to local strategy pivots and leadership changes.

• Operating profit and profit attributable to owners declined sharply YoY, with the Orthopedic Business classified as discontinued.

• Ongoing restructuring, including reduction of ~2,000 positions and new executive appointments, aims to enhance operational execution.

Financial highlights

• Q3 revenue was ¥261.0 billion (+4% YoY after FX adjustment); 9-month revenue was ¥715.4 billion (-1% YoY after FX adjustment).

• Q3 adjusted operating profit was ¥39.3 billion (15.1% margin, -2.1pp YoY); 9-month adjusted operating profit was ¥89.9 billion (-30% YoY).

• Gross margin declined due to ship holds, recalls, and higher U.S. tariffs; Q3 gross margin was 63.2%, down from 66.9% YoY.

• Cash and cash equivalents at period end were ¥169.5 billion, a decrease of ¥83.1 billion from the previous fiscal year-end.

• R&D expenditures for 9 months were ¥80.5 billion, with a full-year forecast of ¥113.0 billion.

Outlook and guidance

• Full-year revenue forecast remains at ¥998 billion, but operating profit guidance was revised down to ¥87–75 billion.

• Adjusted operating margin forecast is 12.7%–13.9% due to ship holds and COGS variability.

• Profit attributable to owners forecast: ¥50.0–59.0 billion; EPS: ¥45–¥53.

• Commitment to 100+ basis points of annual margin improvement and midterm plan for 20%+ operating margin remains.

• Year-end dividend forecast: ¥30 per share.